CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announced that Ares Trading S.A., an affiliate of Merck KGaA, Darmstadt, Germany has exercised a fourth licensing option to develop another bispecific program under the ongoing immuno-oncology collaboration.
News
Innovate UK, the National Institute of Health Research (NIHR; i4i programme and AI in Health and Care Award) and the Small Business Research Initiative (SBRI) Healthcare have joined forces to offer specialist support to companies within their portfolios, from across the UK, via their Investment Readiness Programme. The programme will support selected companies to gain additional skills and expertise to get them prepared to find and attract investment.
Leading pharmaceutical and biotech product development consultancy, Boyds, has hired regulatory expert in the pharma, biotech and medical devices sectors, Eamonn McGowran as Associate Director.
Based at Boyds’ Irish operation at Talent Garden Dublin, Eamonn’s appointment marks the beginning of the next phase of growth and expansion in Dublin and Europe for Boyds, which will harness his leading and specialist regulatory experience in medical devices to boost and enhance its comprehensive regulatory advice and services portfolio.
Click here to view the December 2021 edition of Dates for Your Diary.
Cambridge, UK and Brussels, Belgium 16 December 2021:
Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, and Bioqube Ventures (“Bioqube”), a specialist European life sciences investment firm, announced today that they have entered into a collaboration, backed by Bioqube Factory Fund I, to incubate a drug discovery research project targeting autoimmune diseases.
AMSBIO has expanded its range of custom gene editing services to complement its extensive portfolio of off-the-shelf CRISPR/Cas9 products.
Cambridge UK: 15 December 2021
The PCML Group has become a Partner to join forces with One Nucleus. The One Nucleus Partner Programme is tailor-made to meet the needs of the Partner and One Nucleus members.
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR ANNOUNCES EXCLUSIVE COLLABORATION WITH GLOBAL TECHNOLOGY LEADER
Development of a stable liquid formulation for use within partner’s technology
Cambridge, UK, 14 December 2021: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that it has signed an exclusive formulation study collaboration.
LONDON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, presented further progress on obecabtagene autoleucel (obe-cel) in an oral presentation [Abstract 477] entitled “Industrialization of an Academic Miltenyi Prodigy-Based CAR T Process” at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, being held between December 11-14, 2021.
AMSBIO has announced a new range of kits, media and reagents to assist in the development of cultured meat products - an exciting new area of food technology.